These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 37782874)
1. Racial And Ethnic Disparities In Buprenorphine Receipt Among Medicare Beneficiaries, 2015-19. Miles J; Treitler P; Lloyd J; Samples H; Mahone A; Hermida R; Gupta S; Duncan A; Baaklini V; Simon KI; Crystal S Health Aff (Millwood); 2023 Oct; 42(10):1431-1438. PubMed ID: 37782874 [TBL] [Abstract][Full Text] [Related]
2. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries. Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421 [TBL] [Abstract][Full Text] [Related]
3. Racial Inequality in Receipt of Medications for Opioid Use Disorder. Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624 [TBL] [Abstract][Full Text] [Related]
4. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare. Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120 [TBL] [Abstract][Full Text] [Related]
5. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198 [TBL] [Abstract][Full Text] [Related]
6. Spillover of Medicaid Expansion to Prescribing of Opioid Use Disorder Medications in Medicare Part D. Abraham AJ; Lawler EC; Harris SJ; Bagwell Adams G; Bradford WD Psychiatr Serv; 2022 Apr; 73(4):418-424. PubMed ID: 34407628 [TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. Spivey CA; Wang J; Qiao Y; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M J Manag Care Spec Pharm; 2018 Feb; 24(2):97-107. PubMed ID: 29384031 [TBL] [Abstract][Full Text] [Related]
8. Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder. Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC JAMA Psychiatry; 2022 Dec; 79(12):1173-1179. PubMed ID: 36197659 [TBL] [Abstract][Full Text] [Related]
9. County-level access to opioid use disorder medications in medicare Part D (2010-2015). Abraham AJ; Adams GB; Bradford AC; Bradford WD Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272 [TBL] [Abstract][Full Text] [Related]
10. Racial and Ethnic Disparities in Take-Home Methadone Use for Medicare Beneficiaries With Opioid Use Disorder. Choi S; Zhang Y; Unruh MA; McGinty EE; Jung HY JAMA Netw Open; 2024 Aug; 7(8):e2431620. PubMed ID: 39212993 [TBL] [Abstract][Full Text] [Related]
11. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes. Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793 [TBL] [Abstract][Full Text] [Related]
12. Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. Steve Tsang CC; Wan JY; Chisholm-Burns MA; Li M; Dagogo-Jack S; Cushman WC; Hines LE; Wang J Res Social Adm Pharm; 2021 Aug; 17(8):1469-1477. PubMed ID: 33272859 [TBL] [Abstract][Full Text] [Related]
13. Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US. Dong H; Stringfellow EJ; Russell WA; Jalali MS JAMA Psychiatry; 2023 Jan; 80(1):93-95. PubMed ID: 36350592 [TBL] [Abstract][Full Text] [Related]
14. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States. Parish WJ; Mark TL; Zarkin GA; Weber E Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177 [TBL] [Abstract][Full Text] [Related]
15. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients. Abraham R; Wilkinson E; Jabbarpour Y; Petterson S; Bazemore A J Am Board Fam Med; 2020; 33(1):9-16. PubMed ID: 31907241 [TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Differences in Receipt of Nonpharmacologic Care for Chronic Low Back Pain Among Medicare Beneficiaries With OUD. Bhondoekhan F; Marshall BDL; Shireman TI; Trivedi AN; Merlin JS; Moyo P JAMA Netw Open; 2023 Sep; 6(9):e2333251. PubMed ID: 37698860 [TBL] [Abstract][Full Text] [Related]
18. Explaining Racial-ethnic Disparities in the Receipt of Medication for Opioid Use Disorder during Pregnancy. Gao YA; Drake C; Krans EE; Chen Q; Jarlenski MP J Addict Med; 2022 Nov-Dec 01; 16(6):e356-e365. PubMed ID: 35245918 [TBL] [Abstract][Full Text] [Related]
19. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D. Strickland JC; Huhn AS; Bergeria CL; Strain EC; Dunn KE J Addict Med; 2021 Jul-Aug 01; 15(4):325-333. PubMed ID: 33156180 [TBL] [Abstract][Full Text] [Related]
20. Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. Nathan AS; Yang L; Yang N; Eberly LA; Khatana SAM; Dayoub EJ; Vemulapalli S; Julien H; Cohen DJ; Nallamothu BK; Baron SJ; Desai ND; Szeto WY; Herrmann HC; Groeneveld PW; Giri J; Fanaroff AC JAMA Cardiol; 2022 Feb; 7(2):150-157. PubMed ID: 34787635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]